Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Lung small-RNA transcriptome in cancer and organ development
FY 2019-20
Summary
"Lung cancer has a survival rate of less than 17%, making it the deadliest form of cancer both in Canada and across the world. Diagnosis and treatment of this disease is difficult because most patients appear with symptoms at a late stage, where the cancer has spread and is less vulnerable to therapeutics. Currently, there is a lack of markers to discover disease early, as well as a lack of treatment strategies for these advanced cancers. Normal fetal development resembles tumour growth in many ways, including increased cell growth and invasion into surrounding tissue. In normal development, the fetal genes responsible for these traits are repressed in normal adult tissues. However, in cancerous tissues these fetal genes have been seen to be re-activated during tumour formation. Since fetal genes are not expressed in normal adult cells, these oncofetal sncRNAs may represent a treatment strategy that may prevent toxicity to normal adult cells. Small non-coding RNAs (sncRNAs) are known to regulate gene expression, and have been harnessed by tumours to drive growth. We will sequence sncRNAs from fetal lung tissues, and using our established sncRNA analysis tools, we will compare these genes in fetal samples to those in lung tumours. This comparison will allow us to assess the prevalence of re-activated fetal sncRNAs in lung tumour development. Further, to understand the consequences of these re-activated sncRNAs in the tumour, we will alter the expression of these genes in lung cancer cell models. Through our analyses, we will discover re-activated fetal genes in lung cancer. These genes may represent promising new therapeutic targets with minimal toxicity to normal human cells, and deepen our understanding of sncRNAs and their role in the development of lung cancer."
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429125
Name
Pewarchuk Michelle
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Lung small-RNA transcriptome in cancer and organ development
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Fetal Development; Genomics; Lung Cancer; Microrna
Abstract
"Lung cancer has a survival rate of less than 17%, making it the deadliest form of cancer both in Canada and across the world. Diagnosis and treatment of this disease is difficult because most patients appear with symptoms at a late stage, where the cancer has spread and is less vulnerable to therapeutics. Currently, there is a lack of markers to discover disease early, as well as a lack of treatment strategies for these advanced cancers. Normal fetal development resembles tumour growth in many ways, including increased cell growth and invasion into surrounding tissue. In normal development, the fetal genes responsible for these traits are repressed in normal adult tissues. However, in cancerous tissues these fetal genes have been seen to be re-activated during tumour formation. Since fetal genes are not expressed in normal adult cells, these oncofetal sncRNAs may represent a treatment strategy that may prevent toxicity to normal adult cells. Small non-coding RNAs (sncRNAs) are known to regulate gene expression, and have been harnessed by tumours to drive growth. We will sequence sncRNAs from fetal lung tissues, and using our established sncRNA analysis tools, we will compare these genes in fetal samples to those in lung tumours. This comparison will allow us to assess the prevalence of re-activated fetal sncRNAs in lung tumour development. Further, to understand the consequences of these re-activated sncRNAs in the tumour, we will alter the expression of these genes in lung cancer cell models. Through our analyses, we will discover re-activated fetal genes in lung cancer. These genes may represent promising new therapeutic targets with minimal toxicity to normal human cells, and deepen our understanding of sncRNAs and their role in the development of lung cancer."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pewarchuk, Michelle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~